Shen Qi, Zhou Kaichen, Lu Haosen, Zhang Jielin, Xu Qiqing, Zhang Chengsi, Yang Chunhua, Mao Lijun
Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, Xuzhou, 221002, China.
Department of Radiotherapy, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
Discov Oncol. 2024 Dec 22;15(1):822. doi: 10.1007/s12672-024-01674-x.
High expression of immune checkpoint molecule B7-H3 (CD276) in many cancer types makes it a promising immunotherapeutic target. Both coinhibitory and costimulatory effects of B7-H3 in tumors have been demonstrated, but the mechanism of B7-H3 immune response under dual effects is open to question. B7-H3 is crucially involved in the migration and invasion, angiogenesis, metabolism and chemotherapy resistance of prostate cancer. In addition to the potential immune effects on tumor environment, B7-H3 plays a non-immune-mediated role in tumor progression. In this review, we summarize current understanding of molecular mechanism of B7-H3 in prostate cancer and discuss the potential of B7-H3 as a novel therapeutic target for prostate cancer.
免疫检查点分子B7-H3（CD276）在多种癌症类型中高表达，使其成为一个有前景的免疫治疗靶点。B7-H3在肿瘤中的共抑制和共刺激作用均已得到证实，但其在双重作用下的免疫反应机制尚不清楚。B7-H3在前列腺癌的迁移和侵袭、血管生成、代谢及化疗耐药中起关键作用。除了对肿瘤微环境的潜在免疫作用外，B7-H3在肿瘤进展中还发挥非免疫介导的作用。在本综述中，我们总结了目前对B7-H3在前列腺癌中分子机制的认识，并讨论了B7-H3作为前列腺癌新型治疗靶点的潜力。
